BioCentury
ARTICLE | Emerging Company Profile

Next-gen NMDA

Why Aptinyx aims to modulate rather than block NMDA receptor activity

June 27, 2016 7:00 AM UTC

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA receptor antagonists.

The programs are expected to have better CNS penetration and oral bioavailability than the more advanced peptides of its parent company, which Allergan plc acquired last year for $560 million up front and undisclosed milestones. ...